hnRNPK调控Wnt/β-catenin信号转导通路抑制乳腺癌细胞铁死亡

马小兰, 王娟, 石斌, 王南, 田治翠, 曹佳

  1. 1.宁夏医科大学总医院医学科学研究院,宁夏 银川 750004
    2.宁夏医科大学总医院肿瘤外二科,宁夏 银川 750004
    3.银川市妇幼保健院病理科,宁夏 银川 750004
    4.宁夏医科大学总医院急诊科,宁夏 银川 750004
    5.宁夏医科大学总医院肿瘤内二科,宁夏 银川 750004
    6.灵武市人民医院心血管内科,宁夏 灵武 751400
  • 收稿日期:2024-06-11 修回日期:2024-09-11 出版日期:2024-10-30 发布日期:2024-11-20
  • 通信作者: 曹佳
  • 作者简介:第一作者:马小兰(ORCID:0009-0000-1515-3948),硕士研究生,住院医师。
  • 基金资助:
    宁夏医科大学2024年校级科研项目(XY2024005);宁夏回族自治区重点研发计划项目(2022BEG03124)

摘要/Abstract

摘要:

背景与目的:核内不均一核糖核蛋白K(heterogeneous nuclear ribonucleoprotein K,hnRNPK)是一种调控基因表达和蛋白翻译的RNA结合蛋白,已被发现与多种肿瘤恶性进展密切相关,但其在乳腺癌中的作用尚未明确。本研究旨在探讨hnRNPK对乳腺癌细胞铁死亡的影响及其作用机制。方法:基于癌症基因组图谱(The Cancer Genome Atlas,TCGA)和基因表达综合(Gene Expression Omnibus,GEO)数据库,联合生信分析hnRNPK在乳腺癌组织及正常组织中的表达及与临床预后的关系;采用实时定量逆转录聚合酶链反应(real-time quantitative reverse transcription polymerase chain reaction,qRT-PCR)、蛋白质印迹法(Western blot)、免疫组织化学法检测hnRNPK在乳腺癌细胞及组织中的表达;将乳腺癌MDA-MB-231和MCF-7细胞进行siRNA转染,设置分组为对照组(control)、空载体组(NC)、干扰载体组(si-hnRNPK),采用细胞计数试剂盒(cell counting kit-8,CCK-8)和平板克隆实验检测细胞增殖能力;高通量RNA测序(RNA-sequencing,RNA-seq)分析hnRNPK富集的生物学功能及信号转导通路,Western blot及活性氧(reactive oxygen species,ROS)、丙二醛(malondialdehyde,MDA)、谷胱甘肽(glutathione,GSH)、Fe2+试剂盒检测hnRNPK对铁死亡表型的影响,并利用铁死亡抑制剂(ferrostatin-1,Fer-1)检测敲低hnRNPK对铁死亡的回复作用;通过Western blot检测hnRNPK对Wnt/β-catenin通路蛋白表达的影响。结果:数据库结合生物信息学分析结果显示,hnRNPK在乳腺癌组织中表达上调(P<0.01),hnRNPK高表达组患者总生存期OS低于hnRNPK低表达组(P<0.05);hnRNPK在乳腺癌组织及细胞中呈高表达,敲低hnRNPK后乳腺癌细胞增殖能力减弱(P<0.05);RNA-seq分析发现hnRNPK显著富集铁死亡、凋亡、Wnt/β-catenin信号转导通路;敲低hnRNPK通过促进脂质ROS和MDA产生、Fe2+富集促进乳腺癌细胞铁死亡(P<0.05),且联合Fer-1有效抑制敲低hnRNPK对铁死亡的促进作用(P<0.05);hnRNPK下调导致Wnt/β-catenin信号转导通路中β-catenin、c-Myc表达降低,CK1α、APC、GSK-3β复合物表达升高(P<0.05)。结论:hnRNPK在乳腺癌中呈高表达,敲低hnRNPK通过抑制Wnt/β-catenin信号转导通路促进乳腺癌细胞铁死亡,抑制乳腺癌恶性进展。

关键词: hnRNPK, 乳腺癌, 铁死亡, Wnt/β-catenin信号转导通路

Abstract:

Background and purpose: Heterogeneous nuclear ribonucleoprotein K (hnRNPK) is an RNA special binding protein that participates in regulating the expression of related genes and protein translation. It has been linked to the malignant occurrence and development of various tumors, but its role in breast cancer remains unclear. The aim of this study was to investigate the effects of hnRNPK on ferroptosis in breast cancer cells and the underlying mechanisms. Methods: Based on The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, hnRNPK expression in breast cancer tissues and normal tissues and its relationship with clinical prognosis were analyzed by bioinformatics. We detected hnRNPK expression in breast cancer cells and tissues using real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR), Western blot, and immunohistochemistry staining diagnosis methods. MCF-7 and MDA-MB-231 breast cancer cells were transfected with siRNA, and divided into control group (control), empty body group (NC), and interference vector group (si-hnRNPK). Cell proliferation was detected by cell counting kit-8 (CCK-8) and plate clone formation assays. RNA-seq analysis was applied to explore potential targeted biological functions and signaling pathways affected by hnRNPK. Additionally, we investigated the impact of hnRNPK on ferroptosis phenotype using Western blot and commercial kits for reactive oxygen species (ROS), malondialdehyde (MDA), glutathione (GSH), and Fe2+, ferroptosis inhibitor (ferrostatin-1, Fer-1) was used to detect the rescue effect of hnRNPK knockdown on ferroptosis. The impact of hnRNPK on the expressions of Wnt/β-catenin pathway-related proteins were determined by Western blot. Results: The bioinformatics analyses indicated hnRNPK was upregulated in breast cancer tissues (P<0.01), and the overall survival of patients in the high expression group was poorer compared with those in the low expression group (P<0.05). hnRNPK was highly expressed in breast cancer tissues and cells, and knocking down hnRNPK weakened the proliferation ability of breast cancer cells (P<0.05). The RNA-seq analysis showed that hnRNPK was significantly enriched in ferroptosis, apoptosis, and the Wnt/β-catenin signaling pathway. Knocking down hnRNPK promoted ferroptosis in breast cancer cells by inducing lipid ROS and MDA, as well as Fe2+ accumulation (P<0.05). Interestingly, the ferroptosis inhibitor ferrostatin-1 (Fer-1) reversed the promotive effect of hnRNPK knockdown on ferroptosis (P<0.05). Downregulation of hnRNPK led to a decrease in the expressions of β-catenin and c-Myc in the Wnt/β-catenin signaling pathway, while expressions of CK1α, APC and the GSK-3β complex were elevated (P<0.05). Conclusion: hnRNPK is highly expressed in breast cancer, and knocking down hnRNPK promotes ferroptosis in breast cancer cells by inhibiting the Wnt/β-catenin signaling pathway, thereby suppressing the malignant progression of breast cancer.

Key words: hnRNPK, Breast cancer, Ferroptosis, Wnt/β-catenin pathway

中图分类号: 

相关文章

[1] 徐睿, 王泽浩, 吴炅. 肿瘤相关中性粒细胞在乳腺癌发生、发展中的作用研究进展[J]. 中国癌症杂志, 2024, 34(9): 881-889.
[2] 曹飞, 俞文豪, 唐晓男, 马子冬, 常廷民, 龚亚斌, 廖明娟, 康小红. LINC01410促进食管鳞状细胞癌细胞增殖和迁移的作用及其机制研究[J]. 中国癌症杂志, 2024, 34(8): 753-762.
[3] 曹晓珊, 杨蓓蓓, 丛斌斌, 刘红. 三阴性乳腺癌脑转移治疗的研究进展[J]. 中国癌症杂志, 2024, 34(8): 777-784.
[4] 张剑. 关于女性乳腺癌患者绝经状态判断两个关键问题的临床思考[J]. 中国癌症杂志, 2024, 34(7): 619-627.
[5] 姜丹, 宋国庆, 王晓丹. 乳腺癌中线粒体功能障碍与CPT1A/ERK信号转导通路共同调节乳腺癌恶性行为的机制研究[J]. 中国癌症杂志, 2024, 34(7): 650-658.
[6] 董涧桥, 李坤艳, 李菁, 王斌, 王艳红, 贾红燕. SIRT3通过去乙酰化YME1L1诱导乳腺癌内分泌治疗耐药的作用机制研究[J]. 中国癌症杂志, 2024, 34(6): 537-547.
[7] 郝弦, 黄建军, 杨文秀, 刘晋廷, 张军红, 罗钰蓓, 李青, 王大红, 高玉炜, 谭福云, 薄莉, 郑羽, 王荣, 冯江龙, 李静, 赵春华, 豆晓伟. 乳腺癌原代细胞系为药物筛选和基础研究提供癌症新模型[J]. 中国癌症杂志, 2024, 34(6): 561-570.
[8] 中国抗癌协会乳腺癌专业委员会. 中国早期乳腺癌卵巢功能抑制临床应用专家共识(2024年版)[J]. 中国癌症杂志, 2024, 34(3): 316-333.
[9] 张琪, 修秉虬, 吴炅. 2023年中国乳腺癌重要临床研究成果及最新进展[J]. 中国癌症杂志, 2024, 34(2): 135-142.
[10] 张思源, 江泽飞. 2023年改变晚期乳腺癌临床实践的重要研究成果及进展[J]. 中国癌症杂志, 2024, 34(2): 143-150.
[11] 王昭卜, 黎星, 于鑫淼, 金锋. 2023年改变早期乳腺癌临床实践的重要研究成果及进展[J]. 中国癌症杂志, 2024, 34(2): 151-160.
[12] 罗扬, 孙涛, 邵志敏, 崔久嵬, 潘跃银, 张清媛, 程颖, 李惠平, 杨燕, 叶长生, 于国华, 王京芬, 刘运江, 刘新兰, 周宇红, 柏玉举, 谷元廷, 王晓稼, 徐兵河, 宋礼华. AK-HER2与参照药治疗HER2阳性转移性乳腺癌患者的疗效、体内代谢特征、安全性和免疫原性比较:一项多中心、随机、双盲Ⅲ期等效性临床试验[J]. 中国癌症杂志, 2024, 34(2): 161-175.
[13] 陈远香, 余涛, 杨诗雨, 曾涛, 魏兰, 张彦. KDM4A通过下调BMP9促进乳腺癌细胞MDA-MB-231的迁移和侵袭[J]. 中国癌症杂志, 2024, 34(2): 176-184.
[14] 胡晓钰, 蔡毓文, 叶富贵, 邵志敏, 胡伟刚, 余科达. BRCA1/2胚系突变对三阴性乳腺癌患者放疗后第二原发肿瘤的影响[J]. 中国癌症杂志, 2024, 34(2): 185-190.
[15] 欧阳飞, 王阳, 陈瑜, 裴国清, 王陵, 张扬, 石磊. 基于机器学习构建乳腺癌骨转移预测模型[J]. 中国癌症杂志, 2024, 34(10): 903-914.